Lynx Sees Q4, Full-Year Revenues Drop, Forecasts Strong Growth in 2001 | GenomeWeb

NEW YORK, Feb 21 – Lynx Therapeutics reported a 37 percent drop in fourth-quarter 2000 revenues to $3.3 million, compared with $10.1 million in the year ago quarter, as revenues from technology access and service fees as well as collaborative research fell.

In the fourth quarter, Lynx posted revenues from technology access and service fees of $3.2 million, compared with $5.1 million in fourth-quarter 1999. Revenues from collaborative research plummeted to $125,000, from $5.0 million in the year ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.